Transcript Master Heading - Irish Pharmaceutical Healthcare

Irish Pharmaceutical
Healthcare Association (IPHA)
Annual Meeting
Barry O’Leary
November 25th 2010
Current Impact of FDI
KEY FDI IMPACTS ON THE IRISH
ECONOMY
- €110 BN Exports
- 240,000 Jobs in Total
- 55% of Corporation Tax
- €19 BN Expenditure
- €7 BN Payroll
- 73% of Business RD&I expenditure
WORLD LEADERS CHOOSE IRELAND
- 8 of the top 10 in ICT
- 8 of the top 10 in Pharmaceuticals
- 15 of the top 25 in Medical Devices
- More than 50% of the world’s leading
Financial Services firms
gh
IDA Focus
Business Model Focus
• Global Services
• High-end Manufacturing
• Research, Development & Innovation
Sectors
• Life Sciences - Pharma/Biopharma &
- Medical Devices
• Information & Communications Technology
• Financial Services
• Content Industry, Consumer & Business
Services
• Diversified Industries and Engineering
• CleanTech
FDI 2010 – Recent Wins
Existing Clients
FDI Recent Wins – New Clients
Ireland – major Life Sciences Hub
•
•
Biopharma
Healthcare
Services
Med Tech
•
•
•
8 0f the top 10 Pharma
8 of top 10 and 15 of top 25
Medical Technologies
44,000 jobs
Exports €51 Bn p.a.
Numerous sub-suppiier and
service providers
Recent Lifesciences FDI
Investments
Investing €220m in a new fill finish vaccines facility (170 jobs)
Carlow. EMEA Service Centre in Dublin (150 Jobs).
EMEA Shared Services for 100 people, Cork.
Biologics, €400m investment.
250 person manufacturing expansion in Ballina
€30m investment in bio-analytical / chemistry services, 250 Jobs in Athlone
Global manufacturing and development, 204 people, Dundalk
Investing over €160m in R&D in Galway, Cork and Clonmel
100 person manufacturing expansion in Co. Galway
Expansion of €130m and 170 new jobs
European Services Centre in Dublin, creating more than 200 job.
European Shared Services Centre in Cork - 30 jobs
€50 million new manufacturing investment, creating 250 jobs in Clare
Global Lifesciences Industry
Drivers/Challenges
Pharma
• Patent cliff – increased
generics
• Pipeline Challenge
• Restructuring to
accommodate new reality
– M&A, cost reduction
• Increasing Regulatory
hurdles and costs
• US Healthcare reform –
biosimilars pathway
• Biologics
• Rise of Asia
• Ageing population
• Healthcare reform tax
• 510K regulatory pathway
changes USA
• Convergence – clear
coupling of devices and
tech.
• Asian market growing
strongly
Demand for healthcare to continue to grow
Ageing population
20%+ of population will be over 65 in
developed markets by 2025
Emerging markets
Increasing
demand
Pharma market expected to double by 2015
Copyright © 2010 by The Boston Consulting Group, Inc. All rights reserved.
Unmet needs
Oncology, immunology, antiviral HIV, stroke,
Alzheimer's, obesity, thrombosis, HCV
Broader
offer
1. Source : IMS Market prognosis
New technologies
e.g., Predictive technologies, such as
biomarkers, in silico models
9
Evolution of Pharma Bio
1980s
•
•
•
Single Platform Technology
API manufacturing
Q&A labs
1990s
•
•
•
•
•
•
Sophisticated
manufacturing
Liquids
Tabletting
Creams
Patches
Molecular
diagnostics
2020
2000s
•
•
•
Reference
Global Sites
Biopharma
Shared
services Supply chain,
Regulatory,
Finance
•
•
•
•
•
•
•
•
Commodity
medicines
Self-Dx, Self
Treat
Nutraceuticals
Convergent
technologies
Connected
Health
Personalised
Medicine
Combination
medical
products
Medical Services
Horizon 2020 - Ongoing Evolution of Pharma Bio
2010-2015- Capturing and Delivering marketplace opportunites
•
Integrating disease with lifestyle management
•
Leveraging expertise in nutraceuticals, point of care assays
•
Advancing molecular diagnostics and targetted therapies
•
Utilising genetic testing & biomarkers in advanced clinical trials
•
Developing convergent medical products
•
Rise of bioinfomatics, population health strategies
Now - Building and Developing the sector
•
Winning new biopharma investments
•
Leveraging NiBRT to advance Biopharma Industry
•
Enhancing Ireland’s small molecule Value Proposition
•
Support vaccine development, generic reformulation, improved drug delivery
•
Expanding mandates of top 30 companies “start earlier-finish later”
•
Supporting new starts in packaging, tabletting, labelling, supply chain
•
Expanding footprints into shared services, commercialisation, clinical trials
11
Horizon 2020 - Ongoing Evolution of Pharma Bio
2020 Foresight
• Convergent medical management – drug & dynamic device
• Regenerative Health platforms in ageing, organ, joint replacement
• Connected Health platforms integrating e-health
• Cancer vaccines, targeted personal therapies
• Advancing silver care, aged care, focus on mental wellness
• Tailored health insurance per decade of life
• Development of “polypill”
• Integrated digital medical record and decision support
• Remote monitoring and treatment at home
• New bioactive materials and molecules from marine ecosystem
12
Ireland : A Proven Location for
Lifesciences Service Activities
Initiatives to protect and grow Industry
• Transformation –
–
–
–
–
–
–
•
•
•
•
•
•
•
Technology uplift,
Skills uplift
Process development
Product Development
Energy Efficiency
Operational excellence
Strategic Sites and CMO
NIBRT for Bio
National Commercialisation centre for medical devices
National competence centre for small molecule production
International healthcare services centre
Healthcare Innovation hub with HSE
Research and Development Agenda
Integrated Communications Campaign
• TV Ads
• Live TV Interviews
• Online Media
• Print Media
• Airport Posters
• Press Interviews
• Web Optimisation
Professor Luke O’Neill – Trinity College Dublin
IDA TV Ad – 30 Secs
Thank You